Paragonix touts performance of donor-heart transport technology

  (Image courtesy of Paragonix Technologies) Paragonix Technologies (Braintree, Mass.) said today that its SherpaPak donor-heart transport system has been used successfully at Massachusetts General Hospital in Boston and other transplant centers around the U.S. and Europe. The SheraPak combines cooling technology with safe, consistent methods for cold ischemic storage and transport of donor organs, according to the company, which is also developing and commercializing SherpaLung to transport donated lungs to recipients. Real-time reporting of preservation temperature allows for continuous monitoring of transport conditions of the donor heart. When the transport is completed, these data are downloaded to Bluetooth-enabled devices for record-keeping and sharing among the transplant team. Get the full story on our sister site, Medical Design &Outsourcing. The post Paragonix touts performance of donor-heart transport technology appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Cardiac Implants Cardiovascular Transplants internationalsocietyofheartandlungtransplantation Massachusetts General Hospital Paragonix Technologies Source Type: news

Related Links:

African Americans (AA) have reduced survival compared to Caucasians after heart transplantation (HTx).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
The purpose of this study is to evaluate the utility of vasoactive-inotropic score (VIS) in predicting outcomes after left ventricular assist device (LVAD) implantation and explore possible mechanisms of post-operative hemodynamic instability.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
In this study we describe 2 cases of successful adult DCD HT performed at our institution using an original protocol.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Featured papers Source Type: research
The continuous-flow centrifugal HeartMate 3 left ventricular assist device (Abbott, Abbott Park, IL) is associated with a low risk of de-novo pump thrombosis. In a previous study (the Minimal AnticoaGulation EvaluatioN To aUgment heMocompatibility [MAGENTUM-1] study, ClinicalTrials.gov No. NCT03078374; funded by Abbott and the Ministry of Health, Czech Republic), we reported results of a prospective, observational, pilot trial of reduced intensity warfarin (target international normalized ratio [INR] range 1.5 –1.9) with aspirin in 15 patients implanted with a HeartMate 3 pump and enrolled after 6 weeks.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: RESEARCH CORRESPONDENCE Source Type: research
Conditions:   Acute Leukemia;   CML;   Myelodysplasia;   Lymphoma Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract PURPOSE OF REVIEW: Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation. RECENT FINDINGS: Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of ...
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Tags: Curr Opin Organ Transplant Source Type: research
Purpose of review Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation. Recent findings Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of infection after tran...
Source: Current Opinion in Organ Transplantation - Category: Surgery Tags: ETHICAL CONSIDERATIONS OF ALLOCATION: Edited by David A. Axelrod Source Type: research
More News: Blogging | Cardiology | Cardiovascular | Heart | Heart Transplant | Hospitals | Lung Transplant | Transplant Surgery | Transplants